Table_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx
Background: Granulomatosis with polyangiitis (GPA) patients are prone to disease relapses. We aimed to determine whether GPA patients at risk for relapse can be identified by differences in B cell subset frequencies.
Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). Circulating B cell subset frequencies were analyzed by flow cytometry determining the expression of CD19, CD38, and CD27. B cell subset frequencies at the time of inclusion of future-relapsing (F-R) and non-relapsing (N-R) patients were compared and related to relapse-free survival. Additionally, CD27+CD38hi B cells were assessed in urine and kidney biopsies from active anti-neutrophil cytoplasmic autoantibody-associated vasculitides (AAV) patients with renal involvement.
Results: Within 1.6 years, 30% of patients experienced a relapse. The CD27+CD38hi B cell frequency at the time of inclusion was increased in F-R (median: 2.39%) compared to N-R patients (median: 1.03%; p = 0.0025) and a trend was found compared with the HCs (median: 1.33%; p = 0.08). This increased CD27+CD38hi B cell frequency at inclusion was correlated to decreased relapse-free survival in GPA patients. In addition, 74.7% of patients with an increased CD27+CD38hi B cell frequency (≥2.39%) relapsed during follow-up compared to 19.7% of patients with a CD27+CD38hi B cell frequency of <2.39%. No correlations were found between CD27+CD38hi B cells and ANCA levels. CD27+CD38hi B cell frequencies were increased in urine compared to the circulation, and were also detected in kidney biopsies, which may indicate CD27+CD38hi B cell migration during active disease.
Conclusions: Our data suggests that having an increased frequency of circulating CD27+CD38hi B cells during remission is related to a higher relapse risk in GPA patients, and therefore might be a potential marker to identify those GPA patients at risk for relapse.
History
References
- https://doi.org//10.1056/NEJM199711203372106
- https://doi.org//10.1002/art.37715
- https://doi.org//10.1056/NEJM198806233182504
- https://doi.org//10.1002/art.39450
- https://doi.org//10.1093/rheumatology/ker280
- https://doi.org//10.1056/NEJMoa0909905
- https://doi.org//10.1136/annrheumdis-2014-206404
- https://doi.org//10.1016/j.autrev.2017.12.002
- https://doi.org//10.1093/rheumatology/keu149
- https://doi.org//10.1002/art.24747
- https://doi.org//10.4049/jimmunol.175.12.7867
- https://doi.org//10.1136/ard.52.2.115
- https://doi.org//10.1093/rheumatology/kev293
- https://doi.org//10.3109/03009742.2015.1006247
- https://doi.org//10.1186/1471-2172-15-20
- https://doi.org//10.1146/annurev.immunol.23.021704.115732
- https://doi.org//10.1016/j.immuni.2007.07.009
- https://doi.org//10.1136/ard.2008.096495
- https://doi.org//10.1136/ard.62.9.851
- https://doi.org//10.1186/s13075-017-1231-2
- https://doi.org//10.1155/2016/7651024
- https://doi.org//10.1136/annrheumdis-2014-205233
- https://doi.org//10.1136/annrheumdis-2012-202893
- https://doi.org//10.1016/j.jaut.2017.08.006
- https://doi.org//10.1084/jem.20130323
- https://doi.org//10.4049/jimmunol.1401190
- https://doi.org//10.1371/journal.pone.0182549
- https://doi.org//10.1371/journal.pone.0058140
- https://doi.org//10.4049/jimmunol.1302003
- https://doi.org//10.1086/315832
- https://doi.org//10.1136/ard.2005.044909
- https://doi.org//10.1111/his.13487
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity